Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.52 |
| ▸ | PGK2 | P07205 | 1/20 | 0.52 |
| ▸ | PTPRB | P23467 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914724 | 0.80 | FOLH1 (0.60) | PGK1PGK2FOLH1 | |
| SCHEMBL915496 | 0.78 | ALDH1A1 (0.54) | PGK1PGK2CA12CA1CA2 | |
| SCHEMBL8824567 | 0.78 | PGK1 (0.76) | PGK1PGK2PTPRB | |
| SCHEMBL915468 | 0.77 | PPARD (0.40) | — | |
| SCHEMBL915492 | 0.76 | PGK1 (0.50) | PGK1PGK2PTPRBCA12CA1 | |
| SCHEMBL16749638 | 0.74 | CA12 (0.48) | FOLH1CA12CA1CA2CA7 | |
| SCHEMBL1950244 | 0.74 | CA12 (0.48) | FOLH1CA12CA1CA2CA7 | |
| SCHEMBL29249528 | 0.74 | TSHR (0.41) | FOLH1CA12CA1CA2CA7 | |
| SCHEMBL914774 | 0.74 | SRD5A2 (0.53) | PGK1PGK2CA12CA1CA2 | |
| SCHEMBL914954 | 0.74 | RARB (0.51) | PGK1PGK2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109360974-B | Lithium-sulfur battery positive electrode material based on manganese cluster MOF and preparation method and application thereof | 郑州大学 | 2021-06-11 | — | — | CN | claimed |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | GUILFORD PHARMACEUTICALS INC. | 2005-04-14 | — | — | US | claimed |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| US-20030083505-A1 | Spinal cord injury, demyelinating diseases, Parkinson's disease, Amyotrophic Lateral Sclerosis, alcohol, nicotine, cocaine dependence, neuropathy, pain and schizophrenia; antiischemic, - carcinogenic agents; NAALADase inhibitors | EISAI INC. | 2003-05-01 | — | — | US | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| US-6452044-B2 | NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-09-17 | — | — | US | claimed |
| US-20020019430-A1 | Nervous system and psychological disorders | EISAI INC. | 2002-02-14 | — | — | US | claimed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | claimed |
| WO-2001092273-A2 | BENZENEDICARBOXYLIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| US-20250298333-A1 | POLYESTER RESIN COMPOSITION, ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER, DEVELOPER, AND IMAGE FORMING METHOD | Konica Minolta, Inc. (JP) | 2025-09-25 | — | — | US | disclosed |
| CN-109360974-B | Lithium-sulfur battery positive electrode material based on manganese cluster MOF and preparation method and application thereof | 郑州大学 | 2021-06-11 | — | — | CN | disclosed |
| CN-101208371-B | Method for preparing polyester and polyester manufactured by the method as well as polyester formed body | TOYO BOSEKI | 2011-08-10 | — | — | CN | disclosed |
| US-7868126-B2 | Process for producing polyester, polyester produced using said process, and polyester molded product | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | disclosed |
| WO-2001092273-A2 | BENZENEDICARBOXYLIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001091738-A2 | NAALADASE INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | SMN1; SMN2, GAA, NAALAD2 | PGK1 2047/4885PGK2 2699/4885PTPRB 3541/4885 |
| US-20030083505-A1 | Spinal cord injury, demyelinating diseases, Parkinson's disease, Amyotrophic Lateral Sclerosis, alcohol, nicotine, cocaine dependence, neuropathy, pain and schizophrenia; antiischemic, - carcinogenic agents; NAALADase inhibitors | NGF, GAP43, ACHE | PGK1 2738/4885PGK2 3756/4885PTPRB 2486/4885 |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | HTT, GAA, ADA | PGK1 1289/4885PGK2 1453/4885PTPRB 1497/4885 |
| US-20020019430-A1 | Nervous system and psychological disorders | GLUL, DDC, DNPEP | PGK1 892/4885PGK2 953/4885PTPRB 2753/4885 |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | PGK1 2068/4885PGK2 2587/4885PTPRB 1410/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | PGK1 1143/4885PGK2 1536/4885PTPRB 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.